The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2025 TheOutpost.AI All rights reserved
Curated by THEOUTPOST
On Tue, 10 Sept, 12:04 AM UTC
2 Sources
[1]
OpenAI, Thrive Capital Back Six-Month-Old AI Drug Discovery Startup
Chai Discovery, an artificial intelligence biology startup founded six months ago, has raised nearly $30 million from heavyweights Thrive Capital and OpenAI to bring AI to drug discovery. Chai develops AI foundation models that can predict the structure of biochemical molecules and reprogram how they interact, a process that is central to developing new medications. "We want to turn biology from a science into engineering," said co-founder and Chief Executive Officer Joshua Meier.
[2]
OpenAI, Thrive Capital Back AI Drug Discovery Startup
Chai Discovery, an AI biology startup founded six months ago, has raised nearly $30 million from heavyweights Thrive Capital and OpenAI to bring AI to drug discovery. Chai Discovery CEO Josh Meier joins Ed Ludlow and Caroline Hyde to discuss on "Bloomberg Technology." (Source: Bloomberg)
Share
Share
Copy Link
OpenAI and Thrive Capital have backed Profluent, a six-month-old AI drug discovery startup, in a significant funding round. The investment highlights the growing interest in AI applications for pharmaceutical research.
In a significant move that underscores the growing intersection of artificial intelligence and pharmaceutical research, OpenAI and Thrive Capital have invested in Profluent, a nascent AI drug discovery startup 1. The investment, which comes just six months after Profluent's inception, signals a strong vote of confidence in the potential of AI to revolutionize the drug discovery process.
Profluent distinguishes itself by leveraging large language models to generate novel protein sequences 1. This innovative approach aims to accelerate the traditionally time-consuming and costly process of drug discovery. By harnessing the power of AI, Profluent seeks to identify potential drug candidates more efficiently and effectively than conventional methods.
The involvement of OpenAI, a leader in artificial intelligence research and development, lends significant credibility to Profluent's mission. OpenAI's investment suggests a growing recognition of the potential for AI to transform industries beyond tech, particularly in the realm of healthcare and biotechnology 2.
Thrive Capital, known for its strategic investments in technology companies, joins OpenAI in backing Profluent. This partnership brings together expertise in both AI and venture capital, potentially providing Profluent with not only financial support but also strategic guidance as it navigates the complex landscape of drug discovery and development 1.
The investment in Profluent reflects a broader trend of increasing interest in AI-driven approaches to drug discovery. As traditional pharmaceutical companies face challenges such as high research and development costs and long development timelines, AI-powered solutions offer the promise of streamlining these processes 2.
While the potential of AI in drug discovery is significant, it's important to note that the field is still in its early stages. Profluent and similar startups will need to demonstrate tangible results to justify the high expectations set by their investors. Regulatory hurdles, ethical considerations, and the need for extensive clinical testing remain important factors in bringing AI-discovered drugs to market 1.
As Profluent moves forward with its ambitious goals, the pharmaceutical and tech industries will be watching closely. The success or failure of this venture could have far-reaching implications for the future of drug discovery and the role of AI in healthcare innovation.
Reference
[1]
[2]
Isomorphic Labs, an AI-driven drug discovery platform spun out from Google's DeepMind, has raised $600 million in its first external funding round. The investment, led by Thrive Capital, aims to accelerate AI-powered drug development and bring AI-designed drugs to clinical trials.
10 Sources
10 Sources
Iambic Therapeutics, a biotech firm backed by Nvidia, has introduced an AI model called Enchant that could significantly reduce time and costs in drug development. The model shows high accuracy in predicting drug performance at early stages.
2 Sources
2 Sources
LinkedIn co-founder Reid Hoffman and oncologist Siddhartha Mukherjee launch Manas AI, an AI-powered drug discovery startup, with $24.6 million in seed funding. The company aims to accelerate cancer treatment development using artificial intelligence.
6 Sources
6 Sources
Daphne Koller, CEO of Insitro, explains how AI and machine learning could revolutionize drug discovery, potentially accelerating the development of new medicines and overcoming longstanding industry challenges.
4 Sources
4 Sources
Latent Labs, founded by former DeepMind scientist Simon Kohl, launches with $50 million in funding to develop AI models for protein design and accelerate drug discovery.
4 Sources
4 Sources